Prognosis of Very Low Dose SPECT
Prognosis of Very Low Dose Stress First Myocardial Perfusion SPECT in Patients With Chest Pain Using an Alcyone Camera
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York Presbyterian Hospital- Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients presenting with chest pain but normal or nondiagnostic electrocardiograms and at least 3 negative troponin levels taken 4 or more hours apart.
- Age greater than 18 years.
- Written informed consent is obtained by a study investigator.
Exclusion Criteria:
- Previous Myocardial perfusion scintigraphy (MPS) with evidence of scar
- Previous MPS with evidence of ischemia and no subsequent revascularization
- Known dilated left ventricle
- Known cardiomyopathy
- High pre-test probability of a perfusion defect on MPS
- Body mass index greater than 35
- Prisoner status
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Very low dose stress test protocol
Patients admitted to New York Presbyterian Hospital (NYPH)-Columbia University Medical Center with chest pain but normal or nondiagnostic electrocardiograms and at least 3 negative troponins taken 4 or more hours apart, and undergo exercise or pharmacologic stress testing using a very low dose (<6 mCi) of Tc99m tetrofosmin or sestamibi with imaging performed using acquisitions with an Alcyone camera.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients free of composite endpoint
Time Frame: 3 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
Composite endpoint consists of:
|
3 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients for whom rest imaging is needed.
Time Frame: 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
|
|
Image quality on a 5 point scale
Time Frame: Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
Imagine quality is assessed by 2 readers and is scored on a 5-point scale: excellent, very good, good, fair, poor.
|
Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
|
Average effective dose of radiation received by all patients.
Time Frame: Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
|
|
Average effective dose received by patients for whom stress-only MPS is performed.
Time Frame: Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
|
|
Duration of stress test
Time Frame: Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
|
|
Duration of hospitalization
Time Frame: Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
Up to 12 months after MPS and hospital discharge (an expected average of 12 hours after MPS)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Andrew J Einstein, MD, PhD, NYPH- Columbia University Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AAAI0383
- 10-MYO-003 (Other Grant/Funding Number: GE Healthcare)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.